Tramadol — research review 2

...and this brings us to tramadol, a pain treatment that acts on opioid receptors, but also has SNRI activity. While it can certainly offer relief, research on its long-term use and broader health outcomes is evolving.

Exactly. For some, it’s a crucial medication. But the question is, what does long-term use mean for biological aging and all-cause mortality? We’re seeing studies that raise concerns.

One study in Public Health 2024 (PMID 38718737) noted that chronic opioid use was associated with a 37% higher risk of all-cause mortality compared to short-term use. This isn’t a direct indictment of tramadol alone, but it certainly puts it within that broader conversation.

And when combined with other medications, like gabapentinoids, the risks can increase further. Front Pharmacology 2022 (PMID 36304170) found that such combination therapy could be associated with nearly a triple odds ratio for CNS depression and mortality.

It's a delicate balance because we know untreated pain isn't benign. GeroScience 2025 (PMID 39847262) highlights that painful conditions, like diabetic neuropathy, are linked to accelerated epigenetic aging and telomere shortening. So, effective pain management is also key to healthy aging.

So, for appropriate, supervised use, tramadol clearly has a role. But the long-term safety profile, especially regarding all-cause mortality and potential for serious harms like falls or dependence, is still being rigorously evaluated. What’s still unclear is the precise dose-response relationship over many years, and how these risks compare to the cumulative harm of specific untreated pain conditions.